Rayont Inc.

Equities

RAYT

US75508M1009

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:09:38 2024-04-30 am EDT			5-day change	1st Jan Change
0.1 ^USD	+19,900.00%		-.--%	-.--%

2023	Rayont Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	CI
2023	Rayont Inc. Announces Board Appointments	CI

Rayont, Inc. Reports Earnings Results for the Full Year Ended September 30, 2020

December 18, 2020 at 06:47 am EST

Rayont, Inc. announced earnings results for the full year ended September 30, 2020. For the full year, the company announced sales was USD 186,663. Operating loss was USD 238,862 compared to USD 2.306 million a year ago. Net loss was USD 229,445 compared to USD 2.302 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.26 a year ago.

Latest news about Rayont Inc.

Rayont Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-15	CI
Rayont Inc. Announces Board Appointments	23-02-24	CI
Rayont Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-14	CI
Rayont Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	23-01-17	CI
Rayont Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	22-12-29	CI
Rayont Inc. Auditor Raises 'Going Concern' Doubt	22-12-28	CI
Rayont Inc. Appoints Ilenna Copley as Chief Operating Officer	22-05-20	CI
Rayont Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	22-05-17	CI
Rayont Inc. Announces Management Changes	22-04-25	CI
Rayont Inc. Announces Board Resignations	22-04-22	CI
Rayont Inc. Announces Management Changes	22-03-01	CI
Rayont Inc. Announces Executive Changes	22-03-01	CI
Rayont Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	22-02-24	CI
Rayont Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021	21-11-15	CI
Rayont, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2021	21-05-17	CI
Rayont Inc. Appoints Leilani Latimer as Non-Executive Director	21-04-22	CI
Rayont, Inc. Announces Appointment of Dhurata Toli as Secretary	21-03-26	CI
Rayont Inc Announces Executive Changes	21-03-25	CI
Rayont, Inc. Announces Management Changes	21-03-25	CI
Rayont Inc Appoints Reyad Fezzani as Non-Executive Director and Chairman of the Board	21-03-15	CI
Rayont, Inc. Changes its Fiscal Year End from July 31 to June 30	21-03-03	CI
Rayont : Earnings Flash (RAYT) RAYONT Reports Q4 Revenue $457,865	21-02-16	MT
Rayont, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2020	21-02-16	CI
Rayont, Inc. Announces Fiscal Year Change from September 30 to June 30, Effective December 21, 2020	20-12-21	CI
Rayont, Inc. Reports Earnings Results for the Full Year Ended September 30, 2020	20-12-18	CI

Chart Rayont Inc.

Duration

Period

More charts

Company Profile

Rayont Inc. operates in the personalized natural healthcare sector in United States and Australia. The Company uses scientific tools, such as deoxyribonucleic acid (DNA), microbiome, iridology and other tests to diagnose and personalize the prescription of natural complementary medicine products, services and treatments to its patients in the markets the Company operate. The Company produces a range of products, including proteins, green blends, sports nutrition, weight management and maintenance, and health and wellness products. The Company's subsidiaries include Rayont (Malaysia) Sdn Bhd, Rayont International (L) Limited, Rayont (Australia) Pty Ltd and Prema Life (USA) Inc.

Sector

Biotechnology & Medical Research

Calendar

2024-10-13 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RAYONT INC.	-.--%	4.57M
MODERNA, INC.	+33.37%	50.85B
IQVIA HOLDINGS INC.	+1.55%	42.82B
LONZA GROUP AG	+50.18%	42.03B
CELLTRION, INC.	-4.22%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.57%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	19.13B
BIO-TECHNE CORPORATION	+7.36%	13.05B
MEDPACE HOLDINGS, INC.	+28.30%	12.16B
UNITED THERAPEUTICS CORPORATION	+23.80%	12.08B

Other Biotechnology & Medical Research